Companies › Jecho Biopharmaceuticals
4 active drug programs in 5 registered trials: 5 Phase 1; Oncology, Infectious disease; next expected readout Feb 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| JL18008 IL-18 receptor agonist | – | Phase 1 | HIV Infections | Feb 2027 |
| JL19001 | – | Phase 1 | High Risk Non-muscle Invasive Bladder Cancer; Malignancies | Mar 2027 |
| JLM019 Injection | – | Phase 1 | Advanced Solid Tumor (Phase 1) | Mar 2029 |
| JL15003 Injection | – | Phase 1 | Recurrent Glioblastoma Multiforme(GBM) | Apr 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07579741 | JL18008 | Phase 1 | HIV Infections | Infectious disease | Feb 2027 |
| NCT07483970 | JL19001 | Phase 1 | High Risk Non-muscle Invasive Bladder Cancer | Oncology | Mar 2027 |
| NCT07623850 | JLM019 Injection | Phase 1 | Advanced Solid Tumor (Phase 1) | Oncology | Mar 2029 |
| NCT07501559 | JL15003 Injection | Phase 1 | Recurrent Glioblastoma Multiforme(GBM) | Oncology | Apr 2030 |
| NCT07603479 | JL19001 | Phase 1 | Malignancies | Oncology | May 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.